SVRA 250117 8.00P (SVRA250117P8000) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Jan 24 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Dec 18, 2024 15:09

Update

$Savara (SVRA.US)$ Reuters· just
Savara Initiates Rolling Submission of a Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Apap)

Jaguar8

Dec 1, 2024 01:14

🔵Watchlist Monday December 2. NFA. Trade the Chart. No emotions. No FOMO

NOTE:
1. Not all of these stocks will go up. Everything relies on market sentiment/buy pressure, the satanic shorts including dark pool.
2. The SI CTB and shorts availability are based on 11/29 data and may get updated Monday.
3. NEVER open position without momentum.
4. If you are expecting all stocks to be a runner,then you are set for failure, losses, and bagholding. Not all good news run and not all bad news crash the pri...

Trytosaveabit

Nov 22, 2024 07:08

Watching

$Savara (SVRA.US)$ Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
2 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from...

Jaguar8

Nov 22, 2024 07:07

NEWS

$Savara (SVRA.US)$
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Savara announced an encore presentation of Phase 3 IMPALA-2 trialresults for Molgramostim inhalation solution in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the upcoming British Thoracic Society Winter Meet...

Teddy123

Nov 12, 2024 07:26

In the pipeline

$Savara (SVRA.US)$
After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Savara. “BLA submission, coupled with the submission of the MAA to the EMA by the end of 2025, are major regulatory mileston...